PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. The second to increase in patient-oriented communication and support for physicians.

Education 59

Education Physicians Healthcare Healthcare 59

PM360

NOVEMBER 27, 2023

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Pooja Ojala: How do you approach marketing to adapt to today’s healthcare landscape? Marketing is key to adding that layer of storytelling.

Marketing 105

Marketing Customer Relationship Management Relationship management Education 105

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Marketing 59

Marketing Biopharma Government Pharma 59

European Pharmaceutical Review

NOVEMBER 16, 2023

billion by 2032, according to Towards Healthcare. On the other hand, the author explained that these challenges are anticipated to be addressed through advances in technology, industry effort on implementation of standardisation and increased competition in the market. Could centrifugal bioreactor accelerate cell-therapy manufacturing?

Marketing 71

Marketing Manufacturing Biopharma Competition 71

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

Clarivate

OCTOBER 25, 2023

The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. Impact for patients taking the diabetes drugs and blood thinners might be less noticeable since these drugs tend to receive coverage as preferred brand tiers with copays.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

SEPTEMBER 26, 2023

One of the critical factors determining the success of a clinical trial is the selection of appropriate clinical sites that have evidenced access to specific patient populations. Patient recruitment accounts for 32% of all trial costs and patient drop out averages 18%, according to Deloitte figures. Food and Drug Administration.

Food and Drug Administration 59

Food and Drug Administration Electronics Patients Healthcare 59

European Pharmaceutical Review

DECEMBER 19, 2022

Nonetheless, some stakeholders remain concerned with this new approach given the complexity of biological medicines and the need for patients to be treated individually and have called for further discussions with regulators and all stakeholders. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare.

Medicine 52

Medicine Biopharma Safety Food 52

MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 106

Pharma Food and Drug Administration Recruitment Pharmacology 106

Clarivate

JULY 5, 2023

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

Pharmaceutical Technology

NOVEMBER 23, 2022

One of the primary focus areas includes the continued commercialisation of cutting-edge cell and gene therapies, which involve the modification of cells from patients or donors to produce highly personalised therapies and regenerative medicines. City Competitiveness Index. per square foot (/ft2) in Hamilton, versus C$9.06/ft2

Marketing 52

Marketing Manufacturing Transportation Government 52

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. Driving scale in a slow-moving healthcare ecosystem is not just a challenge for cell and gene therapies.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Pharmaceutical Technology

JUNE 15, 2023

Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. AI and its healthcare applications will continue to evolve, but you can already realize many potential benefits. How is AI used in the pharmaceutical industry?

Pharma 52

Pharma Management Networking Manufacturing 52

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

OCTOBER 19, 2023

The most important benefit is that it can deliver efficacious therapeutics to patients awaiting treatment much faster. Another non-negligible benefit is that it can increase the return on investment for pharmaceutical companies trying to put a new medicine on the market, as compared to traditional drug discovery approaches.

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

MAY 24, 2023

Food and Drug Administration advisory committee’s narrow 8-6 vote in favor of recommending accelerated approval for a first-in-class gene transfer therapy was welcomed by Duchenne muscular dystrophy (DMD) patients and caregivers. Most patients must use a wheelchair by the time they are in their teens.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

MAY 8, 2024

Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

Clarivate

OCTOBER 7, 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. In the following article, we present our analysis of these abstracts and key takeaways for healthcare executives. Context: In August 2021, Merck & Co. Context: In August 2021, Merck & Co.

Patients 91

Patients Safety Marketing Physicians 91

European Pharmaceutical Review

DECEMBER 21, 2022

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.

Manufacturing 71

Manufacturing Pharmaceutical Healthcare Healthcare 71

Clarivate

DECEMBER 1, 2021

Clarivate experts share takeaways from the 2021 American Heart Association Scientific Sessions (AHA21) , with insights on how findings may impact patient care. In the following article, we present our analysis of five featured abstracts and our key takeaways for healthcare executives. 50% in the EMPEROR-Preserved clinical trial 1.

Safety 52

Safety Patients Management Marketing 52

European Pharmaceutical Review

DECEMBER 26, 2023

The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population. These challenges predominantly surround scalability, stability, regulatory compliance and access to patients.

Manufacturing 80

Manufacturing Safety Patients Competition 80

Pharmaceutical Technology

MARCH 21, 2023

The SGLT2 inhibitor is already approved to treat type 2 diabetes (T2D), chronic kidney disease (CKD), and heart failure with reduced ejection fraction (HFrEF) in patients with or without T2D. Baxter Biopharma Solutions is contracted for the parenteral manufacture and packaging of Enhertu.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

JANUARY 25, 2023

In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. Morgan Healthcare Conference in San Francisco, which finished on January 12. But such areas are highly competitive. Download our free whitepaper.

Marketing 69

Marketing Biopharma Pharma Competition 69

Pharmaceutical Technology

JANUARY 15, 2023

On November 30, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) awarded a Great Britain marketing authorization to Aurinia Pharmaceuticals’ Lupkynis (voclosporin) for the treatment of lupus nephritis. The FDA passed several positive supplementary approval decisions involving younger patients.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

Clarivate

DECEMBER 14, 2023

Pharmaceutical benefit managers, M&A activity among integrated delivery networks, disruption by nontraditional healthcare entities, enrollment, and the 2024 presidential election are five areas to pay attention to moving into 2024. Clarivate experts explain why these topics are ones to watch in 2024.

Marketing 52

Marketing Healthcare Healthcare Insurance 52